Tags

Type your tag names separated by a space and hit enter

Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension.
J Cardiovasc Pharmacol. 1987; 10 Suppl 12:S240-3.JC

Abstract

Twenty-three patients with essential hypertension were treated consecutively with prazosin or dihydrochlorothiazide or the combination of the two, each treatment period lasting for three months. Blood pressure, heart rate (HR), serum levels of total cholesterol, triglycerides, HDL-c and LDL-c, uric acid, glucose, Na, and K were measured during the baseline and at the end of each treatment period. Both prazosin and dihydrochlorothiazide (THI) decreased blood pressure but the effect of the combination was more pronounced than that of the monotherapies. Prazosin had no effect on the plasma level of total cholesterol, triglycerides, uric acid, Na, K, and glucose but increased HDL-c, decreased LDL-c, and thereby significantly improved (decreased) atherogenic index (total cholesterol/HDL-c). THI increased total cholesterol, triglycerides, LDL + VLDL-c, glucose, and uric acid; decreased HDL-c and K levels; and significantly increased the atherogenic index. Prazosin neutralized the effects of THI on total cholesterol, triglycerides, HDL-c, and on LDL + VLDL-c but not on glucose, uric acid, or K. These results suggest that the effects of THI on plasma lipids may be mediated by alpha 1-adrenoceptor-related mechanisms but the effects on glucose, uric acid, and K, probably may not be mediated by these mechanisms.

Authors+Show Affiliations

Farsang C
2nd Department of Medicine, Semmelweis University Medical School, Budapest, Hungary.
Péter M
No affiliation info available
Balás-Eltes A
No affiliation info available
Fehér J
No affiliation info available

MeSH

AdultAgedBlood PressureCholesterolFemaleHeart RateHumansHydrochlorothiazideHypertensionLipidsMaleMiddle AgedPrazosinTriglyceridesUric Acid

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

2455187

Citation

Farsang, C, et al. "Prazosin Improves Atherogenic Index and Inhibits the Deleterious Effect of Dihydrochlorothiazide in Patients With Essential Hypertension." Journal of Cardiovascular Pharmacology, vol. 10 Suppl 12, 1987, pp. S240-3.
Farsang C, Péter M, Balás-Eltes A, et al. Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension. J Cardiovasc Pharmacol. 1987;10 Suppl 12:S240-3.
Farsang, C., Péter, M., Balás-Eltes, A., & Fehér, J. (1987). Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension. Journal of Cardiovascular Pharmacology, 10 Suppl 12, S240-3.
Farsang C, et al. Prazosin Improves Atherogenic Index and Inhibits the Deleterious Effect of Dihydrochlorothiazide in Patients With Essential Hypertension. J Cardiovasc Pharmacol. 1987;10 Suppl 12:S240-3. PubMed PMID: 2455187.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension. AU - Farsang,C, AU - Péter,M, AU - Balás-Eltes,A, AU - Fehér,J, PY - 1987/1/1/pubmed PY - 1987/1/1/medline PY - 1987/1/1/entrez SP - S240 EP - 3 JF - Journal of cardiovascular pharmacology JO - J Cardiovasc Pharmacol VL - 10 Suppl 12 N2 - Twenty-three patients with essential hypertension were treated consecutively with prazosin or dihydrochlorothiazide or the combination of the two, each treatment period lasting for three months. Blood pressure, heart rate (HR), serum levels of total cholesterol, triglycerides, HDL-c and LDL-c, uric acid, glucose, Na, and K were measured during the baseline and at the end of each treatment period. Both prazosin and dihydrochlorothiazide (THI) decreased blood pressure but the effect of the combination was more pronounced than that of the monotherapies. Prazosin had no effect on the plasma level of total cholesterol, triglycerides, uric acid, Na, K, and glucose but increased HDL-c, decreased LDL-c, and thereby significantly improved (decreased) atherogenic index (total cholesterol/HDL-c). THI increased total cholesterol, triglycerides, LDL + VLDL-c, glucose, and uric acid; decreased HDL-c and K levels; and significantly increased the atherogenic index. Prazosin neutralized the effects of THI on total cholesterol, triglycerides, HDL-c, and on LDL + VLDL-c but not on glucose, uric acid, or K. These results suggest that the effects of THI on plasma lipids may be mediated by alpha 1-adrenoceptor-related mechanisms but the effects on glucose, uric acid, and K, probably may not be mediated by these mechanisms. SN - 0160-2446 UR - https://www.unboundmedicine.com/medline/citation/2455187/Prazosin_improves_atherogenic_index_and_inhibits_the_deleterious_effect_of_dihydrochlorothiazide_in_patients_with_essential_hypertension_ DB - PRIME DP - Unbound Medicine ER -